Fibroblasts endocytose and degrade transthyretin aggregates in transthyretin-related amyloidosis

Laboratory Investigation

Volumn 93, Issue 8, 2013, Pages 911-920

  Misumi, Yohei ^a,b   Ando, Yukio ^b   Gonçalves, Nádia P ^a,c   Saraiva, Maria J ^a,c  

^a UNIVERSITY OF PORTO   (Portugal)

^b KUMAMOTO UNIVERSITY   (Japan)

^c UNIVERSITY OF PORTO   (Portugal)

Author keywords

Amyloidosis; Endocytosis; Extracellular matrix; Familial amyloidotic polyneuropathy; Fibroblasts; Transthyretin; TTR degradation

Indexed keywords

PREALBUMIN;

AMYLOIDOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENDOCYTOSIS; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; IN VITRO STUDY; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; SKIN BIOPSY;

AMYLOID NEUROPATHIES, FAMILIAL; ANIMALS; DISEASE MODELS, ANIMAL; ENDOCYTOSIS; EXTRACELLULAR MATRIX; FIBROBLASTS; HUMANS; INJECTIONS, SUBCUTANEOUS; LIVER TRANSPLANTATION; MACROPHAGES; MICE; MICE, KNOCKOUT; NIH 3T3 CELLS; PREALBUMIN; SKIN;

EID: 84881050634     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2013.83     Document Type: Article

References (45)

1. Ando Y, Nakamura M, Araki S. Transthyretin-related familial amyloidotic polyneuropathy. Arch Neurol 2005;62: 1057-1062.
2. Rapezzi C, Quarta CC, Riva L, et al. Transthyretin-related amyloidoses and the heart: a clinical overview. Nat Rev Cardiol 2010;7: 398-408.
3. Hammarström P, Jiang X, Hurshman AR, et al. Sequence-dependent denaturation energetics: a major determinant in amyloid disease diversity. Proc Natl Acad Sci USA 2002;99(Suppl 4): 16427-16432.
4. Ihse E, Ybo A, Suhr O, et al. Amyloid fibril composition is related to the phenotype of hereditary transthyretin V30M amyloidosis. J Pathol 2008;216: 253-261.
5. Takahashi K, Yi S, Kimura Y, et al. Familial amyloidotic polyneuropathy type 1 in Kumamoto, Japan: a clinicopathologic, histochemical, immunohistochemical, and ultrastructural study. Hum Pathol 1991; 22: 519-527.
6. Sousa MM, Cardoso I, Fernandes R, et al. Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates. Am J Pathol 2001;159: 1993-2000.
7. Sousa MM, Ferrão J, Fernandes R, et al. Deposition and passage of transthyretin through the blood-nerve barrier in recipients of familial amyloid polyneuropathy livers. Lab Invest 2004;84: 865-873.
8. Santos SD, Fernandes R, Saraiva MJ. The heat shock response modulates transthyretin deposition in the peripheral and autonomic nervous systems. Neurobiol Aging 2010;31: 280-289.
9. Tsuchiya A, Yazaki M, Kametani F, et al. Marked regression of abdominal fat amyloid in patients with familial amyloid polyneuropathy during long-term follow-up after liver transplantation. Liver Transpl 2008;14: 563-570.
10. Tsuchiya-Suzuki A, Yazaki M, Kametani F, et al. Wild-type transthyretin significantly contributes to the formation of amyloid fibrils in familial amyloid polyneuropathy patients with amyloidogenic transthyretin Val30Met. Hum Pathol 2011;42: 236-243.
11. Makover A, Moriwaki H, Ramakrishnan R, et al. Plasma transthyretin. Tissue sites of degradation and turnover in the rat. J Biol Chem 1988;263: 8598-8603.
12. Longo Alves I, Hays MT, Saraiva MJ. Comparative stability and clearance of [Met30]transthyretin and [Met119]transthyretin. Eur J Biochem 1997;249: 662-668.
13. Sousa MM, Saraiva MJ. Internalization of transthyretin. Evidence of a novel yet unidentified receptor-associated protein (RAP)-sensitive receptor. J Biol Chem 2001;276: 14420-14425.
14. Sousa MM, Norden AG, Jacobsen C, et al. Evidence for the role of megalin in renal uptake of transthyretin. J Biol Chem 2000;275: 38176-38181.
15. Fleming CE, Mar FM, Franquinho F, et al. Transthyretin internalization by sensory neurons is megalin mediated and necessary for its neuritogenic activity. J Neurosci 2009;29: 3220-3232.
16. Macedo B, Batista AR, Ferreira N, et al. Anti-apoptotic treatment reduces transthyretin deposition in a transgenic mouse model of Familial Amyloidotic Polyneuropathy. Biochim Biophys Acta 2008; 1782: 517-522.
17. Furuya H, Saraiva MJ, Gawinowicz MA, et al. Production of recombinant human transthyretin with biological activities toward the understanding of the molecular basis of familial amyloidotic polyneuropathy (FAP). Biochemistry 1991;30: 2415-2421.
18. Teixeira PF, Cerca F, Santos SD, et al. Endoplasmic reticulum stress associated with extracellular aggregates. Evidence from transthyretin deposition in familial amyloid polyneuropathy. J Biol Chem 2006; 281: 21998-22003.
19. Cardoso I, Almeida MR, Ferreira N, et al. Comparative in vitro and ex vivo activities of selected inhibitors of transthyretin aggregation: relevance in drug design. Biochem J 2007;408: 131-138.
20. Bolmont T, Clavaguera F, Meyer-Luehmann M, et al. Induction of tau pathology by intracerebral infusion of amyloid-b-containing brain extract and by amyloid-b deposition in APP - Tau transgenic mice. Am J Pathol 2007;171: 2012-2020.
21. Kohno K, Palha JA, Miyakawa K, et al. Analysis of amyloid deposition in a transgenic mouse model of homozygous familial amyloidotic polyneuropathy. Am J Pathol 1997;150: 1497-1508.
22. Misumi Y, Ando Y, Ueda M, et al. Chain reaction of amyloid fibril formation with induction of basement membrane in familial amyloidotic polyneuropathy. J Pathol 2009;219: 481-490.
23. Narindrasorasak S, Altman RA, Gonzalez-DeWhitt P, et al. An interaction between basement membrane and Alzheimer amyloid precursor proteins suggests a role in the pathogenesis of Alzheimer's disease. Lab Invest 1995;72: 272-282.
24. Rhee S. Fibroblasts in three dimensional matrices: cell migration and matrix remodeling. Exp Mol Med 2009;41: 858-865.
25. Yamaguchi H, Yamazaki T, Lemere CA, et al. Beta amyloid is focally deposited within the outer basement membrane in the amyloid angiopathy of Alzheimer's disease. An immunoelectron microscopic study. Am J Pathol 1992;141: 249-259.
26. Tolón RM, Núñ ez E, Pazos MR, et al. The activation of cannabinoid CB2 receptors stimulates in situ and in vitro beta-amyloid removal by human macrophages. Brain Res 2009;1283: 148-154.
27. Argilés A, García García M, Mourad G. Phagocytosis of dialysis-related amyloid deposits by macrophages. Nephrol Dial Transplant 2002;17: 1136-1138.
28. Nyström SN, Westermark GT. AA-Amyloid is cleared by endogenous immunological mechanisms. Amyloid 2012;19: 138-145.
29. Friedrich RP, Tepper K, Rö nicke R, et al. Mechanism of amyloid plaque formation suggests an intracellular basis of Abeta pathogenicity. Proc Natl Acad Sci USA 2010;107: 1942-1947.
30. Kluve-Beckerman B, Manaloor JJ, Liepnieks JJ. A pulse-chase study tracking the conversion of macrophage-endocytosed serum amyloid A into extracellular amyloid. Arthritis Rheum 2002;46: 1905-1913.
31. Biolo A, Ramamurthy S, Connors LH, et al. Matrix metalloproteinases and their tissue inhibitors in cardiac amyloidosis: relationship to structural, functional myocardial changes and to light chain amyloid deposition. Circ Heart Fail 2008;1: 249-257.
32. Miners JS, Baig S, Palmer J, et al. Abeta-degrading enzymes in Alzheimer's disease. Brain Pathol 2008;18: 240-252.
33. Backstrom JR, Miller CA, Tö kés ZA. Characterization of neutral proteinases from Alzheimer-affected and control brain specimens: identification of calcium-dependent metalloproteinases from the hippocampus. J Neurochem 1992;58: 983-992.
34. Sousa MM, do Amaral JB, Guimarães A, et al. Up-regulation of the extracellular matrix remodeling genes, biglycan, neutrophil gelatinaseassociated lipocalin, and matrix metalloproteinase-9 in familial amyloid polyneuropathy. FASEB J 2005;19: 124-126.
35. Cardoso I, Saraiva MJ. Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model. FASEB J 2006;20: 234-239.
36. Cardoso I, Brito M, Saraiva MJ. Extracellular matrix markers for disease progression and follow-up of therapies in familial amyloid polyneuropathy V30M TTR-related. Dis Markers 2008;25: 37-47.
37. Petrakis I, Mavroeidi V, Stylianou K, et al. Human TTRV30M localization within podocytes in a transgenic mouse model of transthyretin related amyloidosis: does the environment play a role? Transgenic Res 2013;22: 101-116.
38. Pokrzywa M, Dacklin I, Vestling M, et al. Uptake of aggregating transthyretin by fat body in a Drosophila model for TTR-associated amyloidosis. PLoS One 2010;5: e14343.
39. O'Neill KD, Chen NX, Wang M, et al. Cellular uptake of beta2M and AGE-beta2M in synovial fibroblasts and macrophages. Nephrol Dial Transplant 2003;18: 46-53.
40. Li W, Poteet E, Xie L, et al. Regulation of matrix metalloproteinase 2 by oligomeric amyloid b protein. Brain Res 2011;1387: 141-148.
41. Wiese S, Karus M, Faissner A. Astrocytes as a source for extracellular matrix molecules and cytokines. Front Pharmacol 2012;3: 120.
42. Wyss-Coray T, Loike JD, Brionne TC, et al. Adult mouse astrocytes degrade amyloid-beta in vitro and in situ. Nat Med 2003;9: 453-457.
43. Lasagna-Reeves CA, Kayed R. Astrocytes contain amyloid-b annular protofibrils in Alzheimer's disease brains. FEBS Lett 2011;585: 3052-3057.
44. Clos AL, Lasagna-Reeves CA, Kelly B, et al. Role of oligomers in the amyloidogenesis of primary cutaneous amyloidosis. J Am Acad Dermatol 2011;65: 1023-1031.
45. Sekijima Y, Tokuda T, Kametani F, et al. Serum transthyretin monomer in patients with familial amyloid polyneuropathy. Amyloid 2001;8: 257-262.